AHNAK2 exacerbates the malignant phenotype of gastric cancer through activation of the Wnt/β-catenin signaling pathway

February 8, 2026Discover OncologyOpen Access

View Full Paper

Ask AI

Bookmark

Share

Key Points

The central aim is to explore how AHNAK2 influences the progression of gastric cancer through specific pathways.
Activated Wnt/beta-catenin signaling pathway analysis
Investigation of AHNAK2 expression levels in gastric cancer cells
Evaluation of AHNAK2 as a potential biomarker and therapeutic target
AHNAK2 expression correlates with increased malignancy in gastric cancer.
Activation of the Wnt/beta-catenin pathway is linked to heightened cancer characteristics.
AHNAK2 shows potential as a prognostic biomarker in gastric cancer.

We only have this paper's title and publication details.

Answers are grounded in this paper and cite their sources.

Reveals AHNAK2's role in promoting malignancy in gastric cancer, suggesting it as a potential therapeutic target.

AHNAK2 may serve as a new prognostic biomarker and a prospective therapeutic target in GC.

No takes yet. Share an insight, caveat, or question.

Liu et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share